Sionna Therapeutics Inc (SION)

$39.21 -0.39 (-0.98%)
Market Cap 1.75B
Revenue (ttm) 0.00
Net Income (ttm) -61.69M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 519,000
Avg Vol 318,586
Day's Range N/A - N/A
Shares Out 44.14M
Stochastic %K 72%
Beta N/A
Analysts Strong Sell
Price Target $38.00

Company Profile

Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 819 2020
Address:
21 Hickory Drive, Suite 500, Waltham, United States
S_Franconi
S_Franconi Oct. 22 at 1:11 PM
$SION Sionna’s ongoing clinical trials, including a Phase 1b trial for SION-451 combinations and a future Phase 2a trial for SION-719, are key catalysts that could validate their approach and potentially lead to significant market adoption. https://www.tipranks.com/news/ratings/buy-rating-for-sionna-therapeutics-innovative-cystic-fibrosis-treatments-with-promising-clinical-trials-ratings
1 · Reply
S_Franconi
S_Franconi Oct. 22 at 12:17 PM
$SION 46 Watchers. 10/22/25
0 · Reply
topstockalerts
topstockalerts Oct. 21 at 11:46 PM
Top Gainers PT2 $ATMV $BOF $SION $YDKG $NAUT
0 · Reply
topstockalerts
topstockalerts Oct. 21 at 8:13 PM
Top Gainers PT2 $ATMV $BOF $SION $RANI $AGRZ
0 · Reply
extrodyne
extrodyne Oct. 21 at 8:00 PM
$SION Big weekly change, closing at the top of the range. Could see a parabolic move tomorrow.
0 · Reply
patb99
patb99 Oct. 21 at 7:25 PM
$SION 😮
1 · Reply
DARKP00L
DARKP00L Oct. 21 at 5:26 PM
$SION 13:24 on Oct. 21 2025 Sionna Therapeutics shares are trading higher. The company initiated its PreciSION CF phase 2a proof-of-concept trial of SION-719. #tradeideas
0 · Reply
S_Franconi
S_Franconi Oct. 21 at 5:14 PM
$SION https://apps.cff.org/trials/pipeline/
0 · Reply
S_Franconi
S_Franconi Oct. 21 at 5:11 PM
$SION Thank you Sion!
0 · Reply
Doozio
Doozio Oct. 21 at 4:01 PM
$SION under radar 💎. Barring a faatch 💣. 🐒🍌🧠⏰♾️
0 · Reply
Latest News on SION
Sionna Therapeutics Announces Presentation of SION-719 and SION-451 Phase 1 Data and Poster of New Preclinical Data on the Impact of NBD1 Stabilizers on F508del-CFTR Half-Life at the 2025 North American Cystic Fibrosis Conference

Oct 24, 2025, 1:15 PM EDT - 22 hours ago

Sionna Therapeutics Announces Presentation of SION-719 and SION-451 Phase 1 Data and Poster of New Preclinical Data on the Impact of NBD1 Stabilizers on F508del-CFTR Half-Life at the 2025 North American Cystic Fibrosis Conference

Sionna Therapeutics Announces Initiation of PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, When Added to Standard of Care in Participants with Cystic Fibrosis

Oct 21, 2025, 7:00 AM EDT - 4 days ago

Sionna Therapeutics Announces Initiation of PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, When Added to Standard of Care in Participants with Cystic Fibrosis

Sionna Therapeutics to Present Data at the 2025 North American Cystic Fibrosis Conference

Oct 1, 2025, 4:05 PM EDT - 23 days ago

Sionna Therapeutics to Present Data at the 2025 North American Cystic Fibrosis Conference

Stock Picks From Seeking Alpha's August 2025 New Analysts

Sep 10, 2025, 9:00 AM EDT - 6 weeks ago

Stock Picks From Seeking Alpha's August 2025 New Analysts

ASML CLF ENPH ESEA FRSH FTK GDX

Sionna Therapeutics, Inc. (SION) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sep 8, 2025, 11:13 AM EDT - 6 weeks ago

Sionna Therapeutics, Inc. (SION) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sionna Therapeutics Appoints Caroline Stark Beer as Chief Business Officer

Sep 8, 2025, 8:00 AM EDT - 6 weeks ago

Sionna Therapeutics Appoints Caroline Stark Beer as Chief Business Officer

Sionna Therapeutics to Participate in Upcoming September Investor Conferences

Aug 27, 2025, 7:00 AM EDT - 2 months ago

Sionna Therapeutics to Participate in Upcoming September Investor Conferences

Sionna Therapeutics Announces First Subjects Dosed in Phase 1 Trial Evaluating NBD1 Stabilizer, SION-451, in Proprietary Dual Combinations in Development for the Treatment of Cystic Fibrosis

Aug 25, 2025, 7:00 AM EDT - 2 months ago

Sionna Therapeutics Announces First Subjects Dosed in Phase 1 Trial Evaluating NBD1 Stabilizer, SION-451, in Proprietary Dual Combinations in Development for the Treatment of Cystic Fibrosis

Sionna Therapeutics Reports Second Quarter 2025 Financial Results

Aug 11, 2025, 7:00 AM EDT - 2 months ago

Sionna Therapeutics Reports Second Quarter 2025 Financial Results

Sionna Therapeutics Announces Presentation of Preclinical Data that Demonstrate Proprietary Dual Combination Therapies Enable Full CFTR Correction in CFHBE Model

Jun 6, 2025, 11:00 AM EDT - 5 months ago

Sionna Therapeutics Announces Presentation of Preclinical Data that Demonstrate Proprietary Dual Combination Therapies Enable Full CFTR Correction in CFHBE Model

Sionna Therapeutics Announces Positive Phase 1 Data for NBD1 Stabilizers SION-719 and SION-451 and Advances Both Programs in Clinical Development for Cystic Fibrosis

Jun 4, 2025, 7:00 AM EDT - 5 months ago

Sionna Therapeutics Announces Positive Phase 1 Data for NBD1 Stabilizers SION-719 and SION-451 and Advances Both Programs in Clinical Development for Cystic Fibrosis

Sionna Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

Jun 3, 2025, 7:00 AM EDT - 5 months ago

Sionna Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

Sionna Therapeutics to Present Preclinical Data During Oral Session at the 48th European Cystic Fibrosis Conference

May 22, 2025, 7:00 AM EDT - 5 months ago

Sionna Therapeutics to Present Preclinical Data During Oral Session at the 48th European Cystic Fibrosis Conference

Sionna Therapeutics Reports First Quarter 2025 Financial Results

May 12, 2025, 7:00 AM EDT - 5 months ago

Sionna Therapeutics Reports First Quarter 2025 Financial Results

Sionna Therapeutics to Present at The Citizens Life Sciences Conference 2025

Apr 30, 2025, 7:00 AM EDT - 6 months ago

Sionna Therapeutics to Present at The Citizens Life Sciences Conference 2025

Sionna Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 20, 2025, 7:00 AM EDT - 7 months ago

Sionna Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Sionna Therapeutics to Present at the 45th Annual TD Cowen Health Care Conference

Feb 24, 2025, 8:00 AM EST - 8 months ago

Sionna Therapeutics to Present at the 45th Annual TD Cowen Health Care Conference

Sionna Therapeutics Announces Closing of $219.2 million Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Feb 10, 2025, 4:03 PM EST - 9 months ago

Sionna Therapeutics Announces Closing of $219.2 million Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

U.S. IPO Weekly Recap: Cement And Cystic Fibrosis Drugs Lead A 6 IPO Week

Feb 8, 2025, 2:30 AM EST - 9 months ago

U.S. IPO Weekly Recap: Cement And Cystic Fibrosis Drugs Lead A 6 IPO Week

AARD AGH EPWK FBGL HCAI KRMN NPB

Sionna Therapeutics Prices Upsized Initial Public Offering

Feb 6, 2025, 7:51 PM EST - 9 months ago

Sionna Therapeutics Prices Upsized Initial Public Offering

U.S. IPO Weekly Recap: Active January Closes Out With Several Sizable IPOs

Feb 1, 2025, 2:10 AM EST - 9 months ago

U.S. IPO Weekly Recap: Active January Closes Out With Several Sizable IPOs

BBNX CSAI INR MAZE MTSR ODTX ODYS

Sionna Therapeutics Seeks $100 Million in IPO For Cystic Fibrosis Treatments

Jan 24, 2025, 1:45 PM EST - 9 months ago

Sionna Therapeutics Seeks $100 Million in IPO For Cystic Fibrosis Treatments

Cystic fibrosis biotech Sionna Therapeutics files for a $100 million IPO

Jan 17, 2025, 7:07 PM EST - 10 months ago

Cystic fibrosis biotech Sionna Therapeutics files for a $100 million IPO

Sionna Therapeutics IPO Registration Document (S-1)

Jan 17, 2025, 5:00 PM EST - 10 months ago

Sionna Therapeutics IPO Registration Document (S-1)

S_Franconi
S_Franconi Oct. 22 at 1:11 PM
$SION Sionna’s ongoing clinical trials, including a Phase 1b trial for SION-451 combinations and a future Phase 2a trial for SION-719, are key catalysts that could validate their approach and potentially lead to significant market adoption. https://www.tipranks.com/news/ratings/buy-rating-for-sionna-therapeutics-innovative-cystic-fibrosis-treatments-with-promising-clinical-trials-ratings
1 · Reply
S_Franconi
S_Franconi Oct. 22 at 12:17 PM
$SION 46 Watchers. 10/22/25
0 · Reply
topstockalerts
topstockalerts Oct. 21 at 11:46 PM
Top Gainers PT2 $ATMV $BOF $SION $YDKG $NAUT
0 · Reply
topstockalerts
topstockalerts Oct. 21 at 8:13 PM
Top Gainers PT2 $ATMV $BOF $SION $RANI $AGRZ
0 · Reply
extrodyne
extrodyne Oct. 21 at 8:00 PM
$SION Big weekly change, closing at the top of the range. Could see a parabolic move tomorrow.
0 · Reply
patb99
patb99 Oct. 21 at 7:25 PM
$SION 😮
1 · Reply
DARKP00L
DARKP00L Oct. 21 at 5:26 PM
$SION 13:24 on Oct. 21 2025 Sionna Therapeutics shares are trading higher. The company initiated its PreciSION CF phase 2a proof-of-concept trial of SION-719. #tradeideas
0 · Reply
S_Franconi
S_Franconi Oct. 21 at 5:14 PM
$SION https://apps.cff.org/trials/pipeline/
0 · Reply
S_Franconi
S_Franconi Oct. 21 at 5:11 PM
$SION Thank you Sion!
0 · Reply
Doozio
Doozio Oct. 21 at 4:01 PM
$SION under radar 💎. Barring a faatch 💣. 🐒🍌🧠⏰♾️
0 · Reply
S_Franconi
S_Franconi Oct. 21 at 2:53 PM
$SION Sionna Therapeutics Announces Initiation of PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, When Added to Standard of Care in Participants with Cystic Fibrosis https://investors.sionnatx.com/news-releases/news-release-details/sionna-therapeutics-announces-initiation-precision-cf-phase-2a
0 · Reply
DARKP00L
DARKP00L Oct. 21 at 11:14 AM
$SION 07:12 on Oct. 21 2025 Sionna Therapeutics Initiates PreciSION CF Phase 2a POC Trial Evaluating SION-719, NBD1 Stabilizer, When Added To Trikafta, Current Standard Of Care In CF; Topline Data Expected In Mid-2026 #tradeideas
0 · Reply
DARKP00L
DARKP00L Oct. 21 at 11:13 AM
$SION 07:04 on Oct. 21 2025 Sionna Therapeutics Initiates PreciSION CF Phase 2a Proof-Of-Concept Trial Of SION-719 #tradeideas
0 · Reply
JarvisFlow
JarvisFlow Oct. 17 at 7:02 PM
Freedom Capital Markets has adjusted their stance on Sionna Therapeutics ( $SION ), setting the rating to Buy with a target price of 38.
1 · Reply
RunnerSignals
RunnerSignals Oct. 16 at 8:31 PM
Comeback Kings on the Move! $SLNO $FATE $SION hit the lows, bounced back, and finished strong!
0 · Reply
heyupikachu1821
heyupikachu1821 Sep. 22 at 11:46 PM
$SION can anyone help me understand why SION is so expensive? I may be missing something, but it seems like they’re fairly early in development, and it seems odd that shares would be trading so high this early. This is not a knock against them or anything. I’m just trying to weigh the risk / reward opportunity here. And right now it seems like (near-term) it’s a high risk, low reward scenario???
5 · Reply
RunnerSignals
RunnerSignals Sep. 9 at 8:50 PM
$ATXS $DNTH $SION $SEZL $SDGR analysts see stars, but will these rockets launch? Strap in, it's gonna be a wild ride! https://stocksrunner.com/news/2025-09-09-unlocking-stocks-with-analyst-upgrades-and-short-term-upside-potential
0 · Reply
StocktwitsNews
StocktwitsNews Sep. 8 at 5:32 AM
Sionna Short Squeeze Fades As Raymond James Backs Cystic Fibrosis Breakthrough, RBC Warns Treatments Set High Bar $SION https://stocktwits.com/news/equity/markets/sionna-short-squeeze-fades-as-raymond-james-backs-cystic-fibrosis-breakthrough-rbc-warns-treatments-set-high-bar/chwWVjjRdA4
0 · Reply
JarvisFlow
JarvisFlow Sep. 3 at 4:57 PM
Raymond James has updated their rating for Sionna Therapeutics ( $SION ) to Strong Buy with a price target of 45.
0 · Reply
Doozio
Doozio Aug. 20 at 3:33 PM
$SION sneaking out on the DLO
0 · Reply
Doozio
Doozio Aug. 18 at 11:10 PM
$SION moar hidden DRUG 💎s during 🐒🍌🧠⏰♾️?
0 · Reply
smartkarma
smartkarma Aug. 13 at 12:03 PM
$SION | Sionna Therapeutics (SION) Six Month Summary: Hot Start, Cold Reality, and a Strong Spring Rebound "​Sionna Therapeutics' successful IPO sees strong market debut with 38.9% premium, fueled by positive Phase I data for Metsera." - IPO Boutique (IPO Boutique) Read more: https://www.smartkarma.com/insights/sionna-therapeutics-sion-six-month-summary-hot-start-cold-reality-and-a-strong-spring-rebound
0 · Reply